In Vitro Efficacy Testing Services for Cytokine Release Syndrome

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Cytokine Release Syndrome (CRS). Our service offers comprehensive analysis of immune cell activation, cytokine production, and key signaling pathways implicated in CRS to support the development of targeted interventions. We focus on critical targets such as T cells, monocytes, cytokines (e.g., IL-6, IFN-γ), and signaling molecules involved in the pathological cytokine cascade. Our assays enable detailed assessment of inflammatory responses, immune modulation, and therapeutic efficacy in mitigating hyperinflammatory processes characteristic of CRS.

Our testing portfolio encompasses a diverse range of biochemical, cell-based, and binding assays designed to evaluate drug efficacy, mechanism of action, and pharmacological activity related to CRS. These methods enable sensitive detection and quantification of cytokine release, cellular responses, and molecular interactions critical for understanding therapeutic impact. Together, they provide a comprehensive platform for in vitro characterization and screening of potential CRS interventions.

ATP assay: Measures cellular viability and metabolic activity by quantifying ATP levels, indicating cytotoxicity or cell proliferation in response to treatments.

ATP assay (at 1 mM): A specialized ATP assay performed at a specific substrate concentration, allowing for standardized comparison of cell viability or metabolic responses.

Behavioral assessment: Evaluates changes in cell behavior or function under experimental conditions, providing insights into immune activation or suppression.

Biolayer interferometry assay: Monitors real-time biomolecular interactions, such as antibody-cytokine binding, to characterize binding kinetics and affinities.

Cell-based assay: Uses live cells to assess functional responses such as cytokine release, immune cell activation, or proliferation, directly relevant to CRS pathology.

Chemiluminescent assay: Detects and quantifies cytokines or signaling molecules using chemiluminescent substrates, offering high sensitivity for low-abundance analytes.

Competitive binding assay: Evaluates the ability of compounds to compete with ligands for receptor binding, useful for characterizing antagonist or inhibitor activity.

Displacement of [125I]-Bolton-Hunter substance P: Measures the displacement of radiolabeled substance P from its receptor, informing on binding specificity and affinity.

Displacement of [125I]-[Sar9,Met(O2)11]-substance P: Assesses ligand-receptor interactions using a modified radiolabeled peptide, providing insights into receptor pharmacology.

Displacement of [125I]-[Tyr8]-substance P: Evaluates competitive binding at the neurokinin receptor using a specific radiolabeled analog.

Displacement of [125I]-substance P: Quantifies the ability of compounds to displace substance P from its receptor, relevant for neuroimmune signaling studies.

Displacement of [3H]-CP-55940: Measures cannabinoid receptor binding and competition, which may modulate immune responses in CRS.

Displacement of [3H]-HU-243: Assesses binding to cannabinoid receptors using a radiolabeled ligand, aiding in the evaluation of immune-modulating compounds.

Displacement of [3H]-ZD-6021: Evaluates drug-receptor interactions using a specific radiolabeled ligand, supporting receptor pharmacology studies.

Displacement of [3H]-[Sar9,Met(O2)11]-substance P: Quantifies competitive binding at neurokinin receptors, important for inflammation and pain signaling.

Displacement of [3H]-substance P: Measures the displacement of radiolabeled substance P, providing data on receptor engagement and affinity.

Displacement of [3H]-vofopitant: Assesses binding to NK1 receptors, which are implicated in inflammatory and immune responses.

Dye assay (trypan blue): Evaluates cell viability by distinguishing live from dead cells based on membrane integrity, a basic measure of cytotoxicity.

ELISA assay: Quantifies cytokine levels and other proteins in cell culture supernatants, enabling precise measurement of inflammatory mediators.

Flow cytometry assay: Profiles immune cell populations and activation states by detecting surface and intracellular markers, supporting detailed immunophenotyping.

Fluorescence resonance energy transfer (FRET) assay: Detects molecular interactions and signaling events in real time based on energy transfer between fluorophores.

Fluorescent assay: Measures cellular or molecular events using fluorescent readouts, allowing high-throughput and sensitive detection.

Fluorescent polarization assay: Assesses binding events and molecular interactions by measuring changes in fluorescence polarization.

Homogeneous Time Resolved Fluorescence (HTRF) assay: Combines fluorescence and time-resolved measurement for sensitive quantification of cytokines or signaling molecules.

Mononuclear cells (blood), human (anti-CD3/anti-CD28/interleukin-2-activated): Uses human blood-derived immune cells activated to mimic CRS conditions, allowing direct assessment of immune-modulating therapies.

Peptide as substrate: Employs specific peptides to assess protease or enzyme activity, relevant for signaling pathway analysis.

RNA assay: Quantifies gene expression levels of cytokines or immune markers, providing mechanistic insights into drug action.

Radioactivity assay: Measures molecular interactions or cellular events using radiolabeled compounds, offering high sensitivity and quantitation.

Surface plasmon resonance assay: Analyzes real-time binding kinetics of biomolecular interactions, essential for characterizing drug-target engagement.

[35S]-GTPgammaS binding assay: Evaluates G protein-coupled receptor activation by measuring GTP binding, relevant for signaling pathway studies.

cAMP accumulation assay: Measures intracellular cAMP levels as an indicator of receptor-mediated signaling, important for immune modulation research.

We measure a suite of quantitative pharmacological parameters to assess drug potency, efficacy, and binding affinity in the context of CRS. These parameters, such as IC-50, EC-50, and Ki, are critical for comparing candidate compounds and optimizing lead selection. Accurate determination of these values informs dose-response relationships and guides preclinical development.

EC-50: The concentration of a compound that produces 50% of its maximal effect; a key indicator of drug potency.

ED-100: The dose required to achieve 100% of the maximum biological response; important for identifying therapeutic windows.

ED-50: The dose at which 50% of the maximal effect is observed; used for potency comparison and dose optimization.

IC-50: The concentration of an inhibitor where the response (or binding) is reduced by half; widely used for screening antagonist efficacy.

Kb: The equilibrium dissociation constant for a competitive antagonist; provides insight into antagonist binding strength.

Kd: The equilibrium dissociation constant for a ligand-receptor complex; reflects the affinity of the ligand for its target.

Ki: The inhibition constant describing the affinity of an inhibitor for its target; essential for comparing inhibitor strengths.

MED: The minimum effective dose, or lowest dose that produces a measurable therapeutic effect; crucial for safety and efficacy assessment.

MIC: The minimum inhibitory concentration, or lowest concentration that inhibits a biological process; important for antimicrobial and anti-inflammatory drug evaluation.

pIC-50: The negative logarithm of the IC-50 value; allows for easier comparison of inhibitor potencies.

pKb: The negative logarithm of the Kb value; indicates antagonist potency in a log scale.

pKi: The negative logarithm of Ki; enables straightforward comparison of inhibitor affinities across compounds.

Recommended In Vitro Efficacy Tests

C-C Motif Chemokine Ligand 5

C-C Motif Chemokine Ligand 5 (CCL5) plays a significant role in immune cell recruitment during Cytokine Release Syndrome (CRS). Accurate CCL5 RNA assays help quantify its expression, aiding in CRS drug evaluation. Determining IC-50 enables assessment of drug efficacy in modulating CCL5-mediated responses. This testing is crucial for optimizing therapeutic candidates targeting inflammatory pathways in CRS drug development.

C-C Motif Chemokine Ligand 8

C-C Motif Chemokine Ligand 8 (CCL8) plays a key role in mediating inflammation during Cytokine Release Syndrome (CRS). Accurate CCL8 testing is essential for CRS drug development to assess therapeutic impact. Our service utilizes biolayer interferometry and ELISA assays to quantify CCL8 levels and interactions, measuring main parameters such as dissociation constant (Kd) and minimum inhibitory concentration (MIC) for robust evaluation of drug efficacy and binding affinity.

C-X-C Motif Chemokine Ligand 10

C-X-C Motif Chemokine Ligand 10 (CXCL10) is a key pro-inflammatory marker in Cytokine Release Syndrome (CRS). Accurate CXCL10 testing is crucial for evaluating drug efficacy and safety in CRS drug development. Our service utilizes RNA assays and ELISA to quantify CXCL10 expression and protein levels. IC-50 values are determined to assess compound potency in modulating CXCL10 response, supporting informed therapeutic decisions.

Cannabinoid Receptor 2

Our Cannabinoid Receptor 2 (CB2) testing service supports Cytokine Release Syndrome drug development by assessing CB2's immunomodulatory role, crucial for controlling inflammatory responses. Using advanced assays—such as competitive binding, [3H]-CP-55940 and [3H]-HU-243 displacement, cAMP accumulation, chemiluminescence, [35S]-GTPγS binding, and HTRF—we determine key pharmacological parameters (EC50, IC50, Ki), enabling precise evaluation of candidate drug efficacy and selectivity.

Interferon Gamma

Interferon Gamma plays a central role in Cytokine Release Syndrome (CRS) by mediating immune activation and inflammation. Accurate Interferon Gamma testing is crucial for evaluating CRS risk during drug development. Our service utilizes flow cytometry assays on human mononuclear cells (stimulated with anti-CD3, anti-CD28, and interleukin-2) to quantify cytokine production. The main parameter measured is the minimum inhibitory concentration (MIC), providing critical insights into immunomodulatory drug safety.

Interleukin 2 Receptor Subunit Alpha

Interleukin 2 Receptor Subunit Alpha (IL-2Rα) plays a pivotal role in modulating immune activation during Cytokine Release Syndrome (CRS). Accurate IL-2Rα testing is crucial for evaluating drug efficacy and safety in CRS drug development. Our service utilizes ELISA assays to quantify IL-2Rα expression, providing key pharmacological parameters such as IC-50 and Kd, essential for characterizing drug-receptor interactions and optimizing therapeutic strategies.

Interleukin 6

Interleukin 6 (IL-6) is a key mediator in Cytokine Release Syndrome (CRS), driving inflammation and immune dysregulation. Accurate IL-6 testing is critical for drug development targeting CRS. We offer ELISA, surface plasmon resonance, RNA, and dye (trypan blue) assays, utilizing human mononuclear cells (anti-CD3/anti-CD28/interleukin-2-activated). Main parameters include ED-50, IC-50, Kd, and MIC, providing essential data for drug efficacy and safety profiling.

Interleukin 6 Receptor

Interleukin 6 Receptor (IL-6R) plays a central role in Cytokine Release Syndrome (CRS) pathogenesis, making its characterization vital for drug development. Our IL-6R testing service utilizes flow cytometry assays to accurately assess receptor binding properties. Key parameters measured include Kd (binding affinity) and MIC (minimum inhibitory concentration), providing essential data for evaluating therapeutic candidates targeting IL-6R in CRS interventions.

Janus Kinase 1

Janus Kinase 1 (JAK1) plays a pivotal role in mediating cytokine signaling implicated in Cytokine Release Syndrome (CRS). Testing JAK1 activity is essential for developing drugs that modulate cytokine storms. Our service uses advanced methods—ATP and chemiluminescent assays, FRET, fluorescent and polarization assays, peptide substrates, HTRF, and cell-based assays—to determine key pharmacological parameters, including IC-50, Kd, and pKi, ensuring robust candidate evaluation for CRS therapies.

Mechanistic Target Of Rapamycin Kinase

The Mechanistic Target Of Rapamycin (mTOR) kinase regulates immune cell activation and cytokine production, playing a crucial role in Cytokine Release Syndrome (CRS) pathogenesis. mTOR kinase testing is vital for evaluating drug candidates targeting CRS. Our service employs sensitive chemiluminescent assays to quantify mTOR activity, providing accurate measurement of the Minimum Effective Dose (MED) required for therapeutic intervention, thus facilitating informed drug development decisions.

Natriuretic Peptide Receptor 1

Natriuretic Peptide Receptor 1 (NPR1) modulates inflammatory responses implicated in Cytokine Release Syndrome (CRS). Testing NPR1 activity is crucial for identifying drug candidates that can mitigate CRS severity. Our service utilizes a sensitive fluorescent assay to quantify NPR1 activation, providing precise EC-50 values for compound efficacy. This enables robust screening and optimization of therapeutics targeting NPR1 in CRS drug development.

Tachykinin Receptor 1

Tachykinin Receptor 1 (NK1R) plays a key role in mediating inflammation and cytokine release in Cytokine Release Syndrome (CRS). Our testing service is vital for evaluating drug candidates targeting NK1R to mitigate CRS. We utilize behavioral assessments, fluorescent and chemiluminescent assays, HTRF, and multiple radioligand displacement methods. Key parameters measured include ED-50, IC-50, Ki, pKi, pIC-50, and MED, ensuring robust characterization of compound efficacy and receptor binding.